Columbia University- Herbert Irving Comprehensive Cancer Center

Key Contacts

Urologic Surgery:
Dr. Christopher Anderson

Urologic Surgery:
Dr. Andrew Lenis

Urologic Surgery:
Dr. James McKiernan

Urologic Surgery:
Dr. Joel DeCastro

Medical Oncology:
Dr. Karie Runcie

Medical Oncology:
Dr. Mark Stein

Medical Oncology:
Dr. Alexander Wei

Medical Oncology:
Dr. Margaux Wooster

Patient Navigator & Appointments:
Call (212) 305-5098

Clinical Trials Contact:
[email protected]
(212) 342-5162

Volume

Metrics reflect this center’s demonstrated experience across key areas of kidney cancer care.

Kidney Cancer Surgery Volume

Medium

Clear Cell Kidney Cancer Diagnosis Volume

Low

Non–Clear Cell Kidney Cancer Diagnosis Volume

Medium

Clinical Trial Participation Volume

High

Radiation & Ablation Procedure Volume

High

About these ratings

Volume and expertise levels are determined using standardized thresholds established by the Kidney Cancer Association and updated annually. Metrics are based on available data and may not reflect the full scope of a center’s capabilities or activity. These metrics are intended to help patients identify centers with demonstrated experience in kidney cancer care.

Types of Services Offered

Clinical Trials

End of Life Services

Genetic Counseling

Infusion Center

Integrated Multidisciplinary Clinic

Integrative Oncology

Molecular Testing

Patient Case Discussions / Tumor Boards

Precision Medicine

Supportive Care / Pain Clinics

Survivorship Clinics

Interventional Radiology

Medical Oncology

Pain Management

Palliative Care

Pathology

Radiation Oncology

Radiology

Urologic Surgery

Kidney Cancer Types & Expertise

Chromophobe RCC Clear Cell RCC Collecting Duct RCC FH-deficient RCC Other Expertise Papillary RCC Renal Medullary Carcinoma Sarcomatoid Translocation RCC Tuberous Sclerosis–associated RCC Unclassified RCC VHL-associated RCC Bilateral Kidney Tumors Complex Recurrent Cases Cystic Renal Tumors Hereditary Syndromes Kidney Transplant Recipients Pediatric (diagnosed under age 18) Pregnancy Solitary Kidney Young Adult (age 18-50)

Other Expertise

CAR T-cell therapy

Special Programs, Recognitions & Outcomes

American College of Surgeons Accredited Cancer Program Government-Funded Research NCI Designated Cancer Center

Research Programs

Clinical

Multi-Institutional Collaboration

Population-Based

Research Lab

Translational

Multi-Institutional Collaborations

NCI National Clinical Trials Network (NCTN)
Experimental Therapeutics Clinical Trials Network (ETCTN)
NYC Academic Medical Collaborations
Translational Research Collaborations (Genomics/Precision Medicine)
Industry-Sponsored Multicenter Trials
Cooperative Group Trials (SWOG, ECOG-ACRIN, Alliance, etc)
New York-Presbyterian System Collaboration

Patient Resources & Support Services

Art Therapy

Fertility Preservation Counseling

Financial Navigators

Interpreter Services

Lodging / Long-Term Housing

Lymphedema Therapy

Music Therapy

Nurse Navigators

Nutrition Services / Dietician

Occupational Therapy

On-site Dispensing / Pharmacy

Parking Assistance (valet or concierge)

Pastoral / Spiritual Care

Patient Navigators

Peer Support Options

Physical Therapy

Psychiatrists / Psychologists

Social Workers / Counselors

Transportation Service

Wellness Center

Insurance Carriers

Accepted

Aetna
Cigna
Blue Cross Blue Shield
UnitedHealthcare/ Oxford
Multiplan/ PHCS networks
Medicare (part B + Advantage plans)
Medicaid (NY+ NJ & Including HARP)
Essential Plan (NY Marketplace tiers)
Child Health Plus (CHP)
World Trade Center Health Program
Healthfirst
Fidelis Care
EmblemHealth (HIP & GHI)
Affinity by Molina Healthcare
Amida Care
Empire BCBS HealthPlus
VNSNY Choice
WellCare
1199 SEIU National Benefit Fund
MagnaCare
NYSHIP

Open Clinical Trials

Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

The study population for this Phase 2 study will include men and women ≥ 18 with confirmed renal cell carcinoma who have progressed on adjuvant anti-PD-1/PD-L1 therapy, the current standard of care. Subjects will be randomized to Arm A or Arm B. Study treatment will be given in 28-day (4 week) cycles. Arm A treatment will consist of zanzalintinib (XL092) alone and will be taken once daily continuously (Day 1-Day 28). Arm B treatment will consist of XL092 plus nivolumab. XL092 will be taken once daily continuously (Day 1-Day 28) and nivolumab will be administered every 4 weeks (Day 1). Treatment will continue until progression by RECIST 1.1, toxicity, or other reasons as appropriate.

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet) and nivolumab + relatlimab (triplet) in participants with advanced solid tumors.<br /> <br /> In the Expansion Stage, the safety and efficacy of zanzalintinib as monotherapy and in combination therapy will be further evaluated in tumor-specific Expansion Cohorts.

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).

ARCITECT

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT)